<?xml version="1.0" encoding="UTF-8"?>
<p id="Par12">The virus-like particles (VLPs), containing repeated antigens but excluding the infective genetic material, are developed as potential vaccine candidates due to their safety and efficacy according to animal experiments [
 <xref ref-type="bibr" rid="CR18">18</xref>–
 <xref ref-type="bibr" rid="CR22">22</xref>]. There’re also two inspiring examples, VLP-based hepatitis B virus and human papillomavirus vaccines, which have been successfully commercialized [
 <xref ref-type="bibr" rid="CR23">23</xref>, 
 <xref ref-type="bibr" rid="CR24">24</xref>]. Recombinant EV71 VLPs can resemble the natural virus structure in terms of their capsid proteins. Immunization with such VLPs can induce EV71-specific immune response with high neutralizing antibody titers and increased cytokines in mouse model [
 <xref ref-type="bibr" rid="CR18">18</xref>, 
 <xref ref-type="bibr" rid="CR25">25</xref>–
 <xref ref-type="bibr" rid="CR27">27</xref>]. Considering the EV71 inactivated whole-virus vaccines are unable to prevent infection caused by other major agents of HFMD, such as CA16, CA10 and CA6, multivalent vaccines deriving from VLPs are regarded as another option for disease prevention [
 <xref ref-type="bibr" rid="CR12">12</xref>, 
 <xref ref-type="bibr" rid="CR24">24</xref>].
</p>
